Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer-8-year results of the breast international group 02-98 phase III trial

Tytuł :
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer-8-year results of the breast international group 02-98 phase III trial
Index Terms :
Hématologie
Cancérologie
Adolescent
Adult
Aged
Antineoplastic Agents -- administration & dosage -- therapeutic use
Antineoplastic Combined Chemotherapy Protocols -- administration & dosage -- therapeutic use
Breast Neoplasms -- drug therapy -- mortality
Cyclophosphamide -- administration & dosage -- therapeutic use
Disease-Free Survival
Doxorubicin -- administration & dosage -- therapeutic use
Drug Administration Schedule
Female
Fluorouracil -- administration & dosage -- therapeutic use
Humans
Lymphatic Metastasis
Methotrexate -- administration & dosage -- therapeutic use
Middle Aged
Taxoids -- administration & dosage -- therapeutic use
Young Adult
Adjuvant
Breast cancer
Chemotherapy
Docetaxel
Doxorubicin
Sequential
info:eu-repo/semantics/article
info:ulb-repo/semantics/articlePeerReview
info:ulb-repo/semantics/openurl/article
Wydawca :
2013-05
Dodane szczegóły :
Oakman, Catherine
Di Leo, Angelo
Francis, Prudence
Crown, John
Quinaux, Emmanuel
Buyse, Marc
Azambuja, Evandro
Punzalan, L.
Piccart-Gebhart, Martine
Vila, Mireia Margeli
Andersson, Michael
Nordenskjöld, B
Jakesz, Raimund
Thürlimann, Beat
Gutiérrez, Jorge Martos J.
Harvey, Vernon
Dell'Orto, Patrizia
Viale, Giuseppe
Larsimont, Denis
Steinberg, I.
Gelber, Richard
Typ dokumentu :
Zasób elektroniczny
URL :
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/183186
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL
Dostępność :
Open access content. Open access content
1 full-text file(s): info:eu-repo/semantics/restrictedAccess
Pozostałe numery :
EQY oai:dipot.ulb.ac.be:2013/183186
uri/info:doi/10.1093/annonc/mds627
uri/info:pii/mds627
uri/info:pmid/23293111
uri/info:scp/84877129418
https://dipot.ulb.ac.be/dspace/bitstream/2013/183186/3/doi_166813.pdf
908369248
Źródło wspomagające :
UNIV LIBR DE BRUXELLES
From OAIster®, provided by the OCLC Cooperative.
Numer akcesji :
edsoai.ocn908369248
Zasób elektroniczny
Background: In women with node-positive breast cancer, the Breast International Group (BIG) 02-98 tested the incorporation of docetaxel (Taxotere) into doxorubicin (Adriamycin)-based chemotherapy, and compared sequential and concurrent docetaxel. At 5 years, there was a trend for improved disease-free survival (DFS) with docetaxel. We present results at 8-year median follow-up and exploratory analyses within biologically defined subtypes. Methods: Patients were randomly assigned to one of four treatments: (i) sequential control: doxorubicin (A) (75 mg/m. 2) × 4 → classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF); (ii) concurrent control: doxorubicin, cyclophosphamide (AC)(60/600 mg/m. 2) × 4 →CMF; (iii) sequential docetaxel: A (75 mg/m. 2) × 3 → docetaxel (T) (100 mg/m. 2) × 3 → CMF and (iv) concurrent docetaxel: AT(50/75 mg/m. 2) × 4 →CMF. The primary comparison evaluated docetaxel efficacy regardless of the schedule. Exploratory analyses were undertaken within biologically defined subtypes. Results: Two thousand eight hundred and eighty-seven patients were enrolled. After 93.4 months of median follow-up, there were 916 DFS events. For the primary comparison, there was no significant improvement in DFS from docetaxel [hazard ratio (HR) = 0.91, 95% confidence interval (CI) = 0.80-1.05, P = 0.187]. In secondary comparisons, sequential docetaxel significantly improved DFS compared with sequential control (HR = 0.81, 95% CI = 0.67-0.99, P = 0.036), and significantly improved DFS (HR = 0.84, 95% CI = 0.72-0.99, P = 0.035) and overall survival (OS) (HR = 0.79, 95% CI = 0.65-0.98, P = 0.028) compared with concurrent doxorubicin-docetaxel. Luminal-A disease had the best prognosis. HRs favored addition of sequential docetaxel in all subtypes, except luminal-A; but this observation was not statistically supported because of limited numbers. Conclusion: With further follow-up, the sequential docetaxel schedule resulted in significantly better OS than concurrent d
SCOPUS: ar.j
info:eu-repo/semantics/published

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies